Yungjin Pharm. Co., Ltd.

KSE 003520.KS

Yungjin Pharm. Co., Ltd. Cash and Short-Term Investments for the year ending December 31, 2023: USD 7.84 M

Yungjin Pharm. Co., Ltd. Cash and Short-Term Investments is USD 7.84 M for the year ending December 31, 2023, a 1,354.51% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

Yungjin Pharm. Co., Ltd. Cash and Short-Term Investments for the year ending December 31, 2022 was USD 538.98 K, a 38.61% change year over year.
Yungjin Pharm. Co., Ltd. Cash and Short-Term Investments for the year ending December 31, 2021 was USD 388.85 K, a -0.96% change year over year.
Yungjin Pharm. Co., Ltd. Cash and Short-Term Investments for the year ending December 31, 2020 was USD 392.62 K, a -30.13% change year over year.
Yungjin Pharm. Co., Ltd. Cash and Short-Term Investments for the year ending December 31, 2019 was USD 561.91 K, a -65.72% change year over year.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

KSE: 003520.KS

Yungjin Pharm. Co., Ltd.

CEO	Mr. Chae-Joon Lee
IPO Date	Jan. 8, 2001
Location	South Korea
Headquarters	13, Olympic-ro 35da-gil
Employees	574
Sector	Healthcare
Industries Pharmaceuticals Cleaning Supplies Drugstores & Retail Pharmacies Non-Alcoholic Beverages Personal Care Pet Food Plastics Soft Drinks & Sodas

Description

Yungjin Pharm. Co., Ltd. operates as a pharmaceutical company in South Korea. It provides cephalosporin antibiotic, antipsychotic, cardiovascular, and nutrition products. The company was founded in 1952 and is headquartered in Seoul, South Korea. Yungjin Pharm. Co., Ltd. is a subsidiary of KT&G Corporation.

Key trends

Past 5 years